Research Paper Volume 12, Issue 4 pp 3848—3861

Establishment and characterization of patient-derived xenografts for hormone-naïve and castrate-resistant prostate cancers to improve treatment modality evaluation

Figure 4. Responses to castration and docetaxel in PDX models. Change in the (A) tumor volume and (B) weight of PDX models after treatment at various time points. (C) Serum tPSA levels in mice bearing PDX tumors after treatment for 30 days. **P < 0.01 compared to the control.